Traditionally, doses of omega-3 ingredients are large, mainly due to their low absorption by the body. This in turn makes adhering to such doses very difficult for consumers.
AquaCelle® formulators can now manufacture smaller doses which increase compliance and tolerance – it is easier to swallow a small capsule without reflux problems once a day compared to several large capsules several times a day .
The health benefits of omega-3 supplementation are widely recognized, but the challenges facing the market:
- Efficiency issues
- Poor consumer compliance
- High dropout due to reflux
- Ecological concerns/sustainability
- Quality issues due to market commoditization
Consumers are looking for conscious consumption choices. According to Innova Market Insights, “Mindful Choice” is the number 1 trend for consumers. In terms of omega-3s, choosing a product that provides a better health outcome and ensures more efficient use of a resource is a powerful ‘X-factor’. Dose reduction supports resource sustainability and ecological concerns within the segment.
AquaCelle® from Pharmako Biotechnologies is a patented delivery system for lipophilic actives such as omega-3 oils, manufactured in a TGA licensed facility, using food-approved ingredients derived from pharmacopoeia standards. AquaCelle® is optimized for reduced excipient levels (as low as 15% for fish oil versus 40% for competitors), with higher bioavailability than competitors.
Pharmacokinetic studies of AquaCelle®-Omega-3 show a six-fold enhancement of omega-3 absorption into blood plasma. The study published in the European Journal of Nutrition1 demonstrated 6x improved absorption and eliminated the “food effect” (the requirement that lipophilic actives be taken with fatty foods). Other studies have been conducted using AquaCelle® formulations for algal oil2krill oil3lutein4 and coenzyme-Q10 5.
AquaCelle® formulations have a unique ability to counter “fish reflux” 3, one of the main reasons for consumer non-compliance.
Omega-3s are important nutrients from an anti-aging perspective. AquaCelle®-Omega-3 formulations address the challenges facing omega-3s in the marketplace.
1 A self-emulsifying formulation of AquaCelle® omega-3 ethyl esters significantly improves the bioavailability of eicosapentaenoic and docosahexaenoic acids in healthy adults. Bremmell, KE, Briskey, D., Meola, TR et al. Eur J Nutr 59, 2729–2737 (2020). doi.org/10.1007/s00394-019-02118-x
2 The effect of dose and AquaCelle® on omega-3 PUFAs absorbed from algal oil containing both EPA and DHA. Briskey D, Rao A (2021)
3 Analysis of AquaCelle® krill oil formulations against various fish oil omega-3 results. Briskey D, Rao A (2020)
4 A study to assess the absorption of 3 (three) formulations of lutein on the increase in plasma lutein concentration and total availability in healthy participants over a period of 72 hours. Briskey D, Mallard A, Rao A (2018)
5 The impact of micelle size and increased absorption of ubiquinone using a new delivery system (AquaCelle®). David Briskey, Andrew T Sax, Alistair R Mallard, Charlie Ng and Amanda Rao. International Journal of Pharmacokinetics vol.4, no.2. doi.org/10.4155/ipk-2019-0004